The Japanese Adverse Drug Event Report (JADER) database, a large, published database managed by the Pharmaceuticals and Medical Devices Agency for pharmacovigilance, collects spontaneous reports as a means to detect adverse events (AEs) related to drugs, and a newly published study used the JADER data to assess AEs related to the reference infliximab and to the biosimilar, CT-P13.
For inflammatory diseases, biosimilar infliximab CT-P13 (Inflectra, Remsima) has provided a more cost-effective option that has expanded access to biologic therapy in many nations, including Japan. The Japanese Adverse Drug Event Report (JADER) database, a large, published database managed by the Pharmaceuticals and Medical Devices Agency for pharmacovigilance, collects spontaneous reports as a means to detect adverse events (AEs) related to drugs, and a newly published study used the JADER data to assess AEs related to the reference infliximab and to the biosimilar.
In the study, published this month in the Journal of Pharmaceutical Health Care and Sciences, the researchers used data from 2014 (when the biosimilar launched in Japan) through 2018 and focused particularly on AEs related to infection. They identified 2771 reports of AEs (494 distinct events) related to the reference infliximab, and 402 reports of AEs (113 distinct events) related to the biosimilar.
Infection-related AEs accounted for 23.7% of reports for the reference infliximab and 21.9% of reports for the biosimilar. Among infection-related AEs associated with the reference, the most common was pneumonia, followed by interstitial lung disease, tuberculosis, and sepsis. Among infection-related AEs associated with the biosimilar, the most commonly reported AEs were pneumonia, followed by interstitial lung disease and sepsis.
Interestingly, write the authors, the reporting odds ratio (ROR) for infection with the biosimilar was 1.48 (95% CI, 0.7-3.13), while the ROR for infection with the reference drug was 3.54 (95% CI, 2.93-4.29); thus, the biosimilar was not associated with infection, while a signal was detected for the reference infliximab.
According to the authors, this observation may be because AE reporting was limited for the biosimilar versus the reference. If reports increase over time, the conclusion may also change, so more studies are warranted. The study was also limited by the fact that JADER data do not allow calculations for true incidence rates, and the fact that ROR does not provide a robust indication of signal strength.
“It is recommended that research be continued in order to accumulate a wide variety of information, and that newly reported data be placed in the multifaceted viewpoints for improvement of care levels,” write the authors.
Reference
Niinomi I, Hoshohata K, Mori Y, et al. Evaluation of adverse events focusing on infection associated with infliximab originator and biosimilar using a spontaneous reporting system database. J Pharm Health Care Sci. 2019;7(5):21. doi: 10.1186/s40780-019-0149-z.
Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry
Published: October 29th 2024 | Updated: October 29th 2024Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
October 15th 2024Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.